253 related articles for article (PubMed ID: 23210851)
21. Monocyclic 4-amino-6-(phenylamino)-1,3,5-triazines as inhibitors of human DNA topoisomerase IIα.
Pogorelčnik B; Brvar M; Zajc I; Filipič M; Solmajer T; Perdih A
Bioorg Med Chem Lett; 2014 Dec; 24(24):5762-5768. PubMed ID: 25453816
[TBL] [Abstract][Full Text] [Related]
22. Nature-inspired substituted 3-(imidazol-2-yl) morpholines targeting human topoisomerase IIα: Dynophore-derived discovery.
Herlah B; Janežič M; Ogris I; Grdadolnik SG; Kološa K; Žabkar S; Žegura B; Perdih A
Biomed Pharmacother; 2024 Jun; 175():116676. PubMed ID: 38772152
[TBL] [Abstract][Full Text] [Related]
23. HMGB1 interacts with human topoisomerase IIalpha and stimulates its catalytic activity.
Stros M; Bacíková A; Polanská E; Stokrová J; Strauss F
Nucleic Acids Res; 2007; 35(15):5001-13. PubMed ID: 17636313
[TBL] [Abstract][Full Text] [Related]
24. Quinolino[3,4-b]quinoxalines and pyridazino[4,3-c]quinoline derivatives: Synthesis, inhibition of topoisomerase IIα, G-quadruplex binding and cytotoxic properties.
Palluotto F; Sosic A; Pinato O; Zoidis G; Catto M; Sissi C; Gatto B; Carotti A
Eur J Med Chem; 2016 Nov; 123():704-717. PubMed ID: 27521587
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-β-benzyl ester derivatives as potent topoisomerase IIα inhibitors.
Han X; Zhong Y; Zhou G; Qi H; Li S; Ding Q; Liu Z; Song Y; Qiao X
Bioorg Med Chem; 2017 Jun; 25(12):3116-3126. PubMed ID: 28462840
[TBL] [Abstract][Full Text] [Related]
26. Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.
Dickey JS; Osheroff N
Biochemistry; 2005 Aug; 44(34):11546-54. PubMed ID: 16114891
[TBL] [Abstract][Full Text] [Related]
27. CS1 is a novel topoisomerase IIα inhibitor with favorable drug resistance profiles.
Shen Y; Chen W; Zhao B; Hao H; Li Z; Lu C; Shen Y
Biochem Biophys Res Commun; 2014 Oct; 453(3):302-8. PubMed ID: 25242524
[TBL] [Abstract][Full Text] [Related]
28. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
29. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
[TBL] [Abstract][Full Text] [Related]
30. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
Pourpak A; Landowski TH; Dorr RT
J Pharmacol Exp Ther; 2007 Jun; 321(3):1109-17. PubMed ID: 17351106
[TBL] [Abstract][Full Text] [Related]
31. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
32. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.
Bau JT; Kang Z; Austin CA; Kurz EU
Mol Pharmacol; 2014 Feb; 85(2):198-207. PubMed ID: 24220011
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.
Jun KY; Lee EY; Jung MJ; Lee OH; Lee ES; Park Choo HY; Na Y; Kwon Y
Eur J Med Chem; 2011 Jun; 46(6):1964-71. PubMed ID: 21419530
[TBL] [Abstract][Full Text] [Related]
34. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
35. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
[TBL] [Abstract][Full Text] [Related]
36. Coordinating the two protomer active sites of human topoisomerase IIalpha: nicks as topoisomerase II poisons.
Deweese JE; Osheroff N
Biochemistry; 2009 Feb; 48(7):1439-41. PubMed ID: 19166355
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, biological evaluation and modeling studies of terphenyl topoisomerase IIα inhibitors as anticancer agents.
Qiu J; Zhao B; Zhong W; Shen Y; Lin H
Eur J Med Chem; 2015 Apr; 94():427-35. PubMed ID: 25800514
[TBL] [Abstract][Full Text] [Related]
38. Human topoisomerase IIalpha rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks.
McClendon AK; Rodriguez AC; Osheroff N
J Biol Chem; 2005 Nov; 280(47):39337-45. PubMed ID: 16188892
[TBL] [Abstract][Full Text] [Related]
39. Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.
Bower JJ; Karaca GF; Zhou Y; Simpson DA; Cordeiro-Stone M; Kaufmann WK
Oncogene; 2010 Aug; 29(34):4787-99. PubMed ID: 20562910
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of friedelan triterpenoid analogs with DNA topoisomerase IIα inhibitory activity and their molecular docking studies.
Mandal A; Ghosh S; Bothra AK; Nanda AK; Ghosh P
Eur J Med Chem; 2012 Aug; 54():137-43. PubMed ID: 22633831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]